Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, 1275 York Avenue, New York, NY 10065, USA.
Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, 1275 York Avenue, New York, NY 10065, USA.
Cancer Cell. 2020 Apr 13;37(4):443-455. doi: 10.1016/j.ccell.2020.03.017.
Immune checkpoint inhibitors (ICIs) have rapidly altered the treatment landscape for multiple tumor types, providing unprecedented survival in some patients. Despite the characteristic durability of response to ICI, unfortunately many patients with initial response will later develop acquired resistance. The current understanding of mechanisms of acquired resistance to ICIs is remarkably limited, perhaps restraining effective development of next-generation immunotherapies. Here, we examine the barriers to progress and emerging clinical reports interrogating acquired resistance with the goal to facilitate efforts to overcome acquired resistance to ICIs in the future.
免疫检查点抑制剂 (ICIs) 迅速改变了多种肿瘤类型的治疗格局，为一些患者提供了前所未有的生存机会。尽管对 ICI 的反应具有特征性的持久性，但不幸的是，许多最初有反应的患者后来会发展出获得性耐药。目前对获得性 ICI 耐药机制的理解非常有限，这可能限制了下一代免疫疗法的有效开发。在这里，我们检查了阻碍进展的因素和新兴的临床报告，以探讨获得性耐药，旨在促进未来克服 ICI 获得性耐药的努力。
